Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 129   

Articles published

NVO 57.54 -0.09 (-0.16%)
price chart
Novo Nordisk A/S (ADR) Stock Surges On Increased Profit And Sales
Novo Nordisk A/S (ADR) (NYSE:NVO) announced its earnings for the first quarter of 2015 and the financial guidance for the full year 2015, and said that its current chief executive officer, Lars Rebien Sorensen, will remain at the helm of the company ...
Novo Nordisk Posts Rise In Profit  Benzinga
Large Cap Stocks Investor's Alert - Novo Nordisk (NVO), CVS Health (CVS ...  Techsonian (press release)
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) (NYSE:NVO) close to 52-week high, short interest surging
Novo Nordisk A/S (ADR) (NYSE:NVO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $56.27, up by 1.22%, with a volume of 1,155,117 shares against an average volume for the last 3 months of 1,713,340.
Novo Nordisk A/S (ADR) (NYSE:NVO)'s 1Q Report; Rise in Earnings from ...  Investor Newswire
Worth Watching Healthcare Sector Stocks- Gilead Sciences, Inc. (GILD ...  Investor Wired
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Novo Nordisk A/S (ADR) (NYSE:NVO) Resubmits Application for Approval of Its ...  WallStreet.org
Hot Stocks on the Run: Alibaba Group Holding Ltd (NYSE:BABA), Novo Nordisk ...  wsnewspublishers
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Novo Nordisks Saxenda Gets EU Approval for Obesity  Zacks.com
Form 6-K NOVO NORDISK AS For: Mar 23  StreetInsider.com
Novo Nordisk A/S (ADR) Anticipates Price Gains For Its Insulin Drugs Even As ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is optimistic about the company's ability to charge high prices for its diabetes products this year and the next year, despite increased competition in the market from Sanofi SA (ADR) (NYSE:SNY) as well as other ...
Novo Nordisk A/S (ADR) (NYSE:NVO) Trying to Increase Market Share  WallStreet.org
Latest Updates on Novo Nordisk A/S (ADR) (NYSE:NVO)
The injectable drug is the second obesity treatment to be approved by the FDA this year; the first obesity-related treatment, approved in September, was Contrave, an oral medicine by Orexigen Therapeutics Inc. (NASDAQ:OREX).
Novo Nordisk (NVO) Searching For A New CEO  Bidness ETC
Related articles »  
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among ...
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other funds to begin the process of looking into and setting up their own ...
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.